Avalo Therapeutics (NASDAQ:AVTX) Research Coverage Started at Wolfe Research

Wolfe Research started coverage on shares of Avalo Therapeutics (NASDAQ:AVTX) in a research note released on Wednesday morning, MarketBeat.com reports. The firm issued an outperform rating and a $48.00 price target on the stock.

A number of other research firms have also commented on AVTX. Weiss Ratings restated a “sell (d-)” rating on shares of Avalo Therapeutics in a research report on Friday, January 9th. HC Wainwright boosted their target price on shares of Avalo Therapeutics from $25.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday, March 25th. Wall Street Zen raised shares of Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Sunday, March 29th. BTIG Research reaffirmed a “buy” rating and issued a $40.00 target price on shares of Avalo Therapeutics in a research note on Tuesday, March 24th. Finally, Citizens Jmp began coverage on shares of Avalo Therapeutics in a research note on Monday, April 6th. They issued an “outperform” rating and a $52.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $44.83.

Avalo Therapeutics Stock Performance

Shares of Avalo Therapeutics stock opened at $13.66 on Wednesday. The firm’s 50-day simple moving average is $15.49 and its 200-day simple moving average is $16.09. Avalo Therapeutics has a twelve month low of $3.39 and a twelve month high of $20.72. The firm has a market cap of $311.31 million, a P/E ratio of -2.38 and a beta of 0.93.

Avalo Therapeutics (NASDAQ:AVTX) last issued its earnings results on Monday, March 23rd. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($1.54) by $1.17. The business had revenue of $0.06 million for the quarter, compared to analyst estimates of ($0.21) million. On average, equities analysts forecast that Avalo Therapeutics will post -19.07 earnings per share for the current fiscal year.

Insider Buying and Selling at Avalo Therapeutics

In other news, CFO Christopher Ryan Sullivan sold 7,980 shares of Avalo Therapeutics stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $17.15, for a total value of $136,857.00. Following the completion of the sale, the chief financial officer owned 17,338 shares in the company, valued at $297,346.70. The trade was a 31.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mittie Doyle sold 3,970 shares of the business’s stock in a transaction on Monday, April 6th. The shares were sold at an average price of $18.01, for a total transaction of $71,499.70. Following the sale, the insider owned 3,622 shares of the company’s stock, valued at $65,232.22. This trade represents a 52.29% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 46,100 shares of company stock valued at $764,724 in the last quarter. 3.03% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Avalo Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Orbimed Advisors LLC raised its stake in Avalo Therapeutics by 39.5% in the third quarter. Orbimed Advisors LLC now owns 1,349,300 shares of the company’s stock valued at $17,150,000 after purchasing an additional 382,300 shares in the last quarter. Nantahala Capital Management LLC raised its stake in shares of Avalo Therapeutics by 24.1% during the third quarter. Nantahala Capital Management LLC now owns 1,235,000 shares of the company’s stock worth $15,697,000 after acquiring an additional 240,000 shares in the last quarter. Affinity Asset Advisors LLC raised its stake in shares of Avalo Therapeutics by 4.5% during the fourth quarter. Affinity Asset Advisors LLC now owns 1,051,054 shares of the company’s stock worth $19,087,000 after acquiring an additional 44,837 shares in the last quarter. Caligan Partners LP raised its stake in shares of Avalo Therapeutics by 5.8% during the fourth quarter. Caligan Partners LP now owns 881,533 shares of the company’s stock worth $16,009,000 after acquiring an additional 48,200 shares in the last quarter. Finally, Balyasny Asset Management L.P. purchased a new position in shares of Avalo Therapeutics during the third quarter worth approximately $10,390,000. 87.06% of the stock is owned by hedge funds and other institutional investors.

More Avalo Therapeutics News

Here are the key news stories impacting Avalo Therapeutics this week:

• Positive Sentiment: Wolfe Research initiated coverage with an “Outperform” rating and a $48 price target (about a 250% upside vs. the current share price). This is a strong institutional endorsement that can attract buy-side interest and rerate the stock if Wolfe’s clinical/financial thesis gains traction. Wolfe Research initiates coverage of Avalo Therapeutics (AVTX) with outperform recommendation
• Positive Sentiment: Recent broker coverage shows elevated analyst targets and a moderate-buy consensus (market sources cite ~$42–44 consensus targets), which supports upside expectations from sell-side research. Avalo Therapeutics (NASDAQ:AVTX) Receives $42.25 Consensus Target Price from Brokerages
• Neutral Sentiment: One April 10 data entry reporting “0 shares” shorted appears to be a reporting glitch or NaN error and conflicts with the March 31 short-interest filing; treat that specific datapoint as unreliable until corrected by the exchange.
• Negative Sentiment: Short interest jumped on March 31 to ~5.54M shares (up ~35.5% vs. mid‑March), representing about 25.1% of shares outstanding with a days-to-cover of ~6.2 based on average volume — a significant short base that can weigh on the stock and increase downside pressure and volatility if selling accelerates.
• Negative Sentiment: Insider selling: Director/officer Mittie Doyle sold 3,970 shares on April 6 at ~$18 (part of prior Rule 10b5-1 sales). Repeated insider sales (including earlier larger dispositions) can be interpreted negatively by investors, even if pre‑arranged. SEC filing: SEC Form 4 filing for Mittie Doyle

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.